Apogee Therapeutics, Inc. 8-K

What Happened
Apogee Therapeutics, Inc. announced a business update and reported its financial results for the quarter ended March 31, 2026. The company filed a Current Report on Form 8‑K on May 11, 2026 furnishing an Earnings Press Release containing the quarterly results.

Key Details

• The 8‑K was filed on May 11, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• The Earnings Press Release is furnished as Exhibit 99.1 to the Form 8‑K and is incorporated by reference.
• The filing also includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.
• The report was signed by CEO Michael Henderson, M.D.

Why It Matters
This filing notifies investors that Apogee has released its quarterly earnings and a business update; the press release (Exhibit 99.1) will contain the specific revenue, profit/loss, and operating highlights that drive short‑term stock and analyst reactions. Retail investors should read the Earnings Press Release and the company’s financial statements for the quarter ended March 31, 2026 to evaluate performance and any commentary on guidance or business outlook.